Clinical Trials Browser

Phase 2 × Small Cell Lung Carcinoma × MLN 8237 × Clear all

NCT07465757 2026-03-12

ALISCA-Lung2

Phase 2 Not yet recruiting

Small Cell Lung Carcinoma

NCT06095505 2026-02-17

ALISCA-Lung1

Phase 2 Recruiting

Small Cell Lung Carcinoma

NCT02038647 2018-12-27

Phase 2 Study of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)

Phase 2 Completed

178 enrolled 27 charts

Small Cell Lung Carcinoma